Home › Cancro ovarico › Indiana › Indianapolis
Studi clinici su Cancro ovarico a Indianapolis, IN
17 studi su Cancro ovarico cercano partecipanti presso sedi a Indianapolis e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
In reclutamentoFase 1
- IU Simon Cancer Center, Indianapolis
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
In reclutamentoFase 2
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492, Indianapolis
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
In reclutamentoFase 2
- Site 0284 - Community Cancer Center North, Indianapolis
- Site 0217 - St Vincent Hospital and Health Care Centers, Indianapolis
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
In reclutamentoFase 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
In reclutamentoFase 1
- Indiana University (IU) School of Medicine, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Community Health Network, Indianapolis
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
In reclutamentoFase 3
- Franciscan Health Indianapolis ( Site 0081), Indianapolis
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
In reclutamentoFase 3
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
In reclutamentoFase 1
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
In reclutamentoFase 1/2
- Riley Hospital for Children, Indianapolis
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
In reclutamentoFase 1
- Indiana University, Indianapolis
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
In reclutamento
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
In reclutamentoFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
- e altri 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Community Health Network, Indianapolis
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
In reclutamentoFase 2/3
- Community Health Network - MD Anderson, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
In reclutamentoFase 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- e altri 1
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
In reclutamentoFase 3
- Indiana University, Indianapolis
Studi su Cancro ovarico in altre città
- Houston, TX89 studi
- New York City, NY69 studi
- Boston, MA61 studi
- Los Angeles, CA50 studi
- Nashville, TN49 studi
- Arlington, VA46 studi
- Philadelphia, PA44 studi
- Columbus, OH39 studi
- St. Louis, MO38 studi
- Chicago, IL36 studi
- San Antonio, TX31 studi
- Cleveland, OH30 studi
Altri studi a Indianapolis
- Cancro del polmone non a piccole cellule32 studi
- Cancro (tutti i tipi)24 studi
- Insufficienza cardiaca23 studi
- Obesità20 studi
- Cancro al seno20 studi
- Cancro metastatico19 studi
- Cancro colorettale18 studi
- Malattie cardiovascolari17 studi
- Cancro ai polmoni16 studi
- Diabete di tipo 114 studi
- Cancro dell'endometrio14 studi
- Morbo di Alzheimer14 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.